Loading...

Valeo Pharma

CNSX:VPH
Snowflake Description

Worrying balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
VPH
CNSX
CA$26M
Market Cap
  1. Home
  2. CA
  3. Healthcare
Company description

Valeo Pharma Inc. acquires and markets specialty products, and markets and distributes third-party pharmaceutical products. The last earnings update was 51 days ago. More info.


Add to Portfolio Compare Print
VPH Share Price and Events
7 Day Returns
0%
CNSX:VPH
0.2%
CA Healthcare
1.3%
CA Market
1 Year Returns
-
CNSX:VPH
19.4%
CA Healthcare
-2%
CA Market
VPH Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Valeo Pharma (VPH) 0% -22.5% -23.6% - - -
CA Healthcare 0.2% -2.6% -2.3% 19.4% -4.5% 29%
CA Market 1.3% -0.1% 0.2% -2% 12% 3.1%
1 Year Return vs Industry and Market
  • No trading data on VPH.
  • No trading data on VPH.
Price Volatility
Industry
5yr Volatility vs Market

Value

 Is Valeo Pharma undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.

In this section, we usually try to help investors determine whether Valeo Pharma is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Valeo Pharma has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.

Show me the analysis anyway

INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Valeo Pharma. This is due to cash flow or dividend data being unavailable. The share price is CA$0.55.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Valeo Pharma's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Valeo Pharma's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
CNSX:VPH PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-01-31) in CAD CA$-0.07
CNSX:VPH Share Price ** CNSX (2019-06-13) in CAD CA$0.55
Canada Healthcare Industry PE Ratio Median Figure of 7 Publicly-Listed Healthcare Companies 45.98x
Canada Market PE Ratio Median Figure of 543 Publicly-Listed Companies 15.36x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Valeo Pharma.

CNSX:VPH PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= CNSX:VPH Share Price ÷ EPS (both in CAD)

= 0.55 ÷ -0.07

-7.63x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Valeo Pharma is loss making, we can't compare its value to the CA Healthcare industry average.
  • Valeo Pharma is loss making, we can't compare the value of its earnings to the Canada market.
Price based on expected Growth
Does Valeo Pharma's expected growth come at a high price?
Raw Data
CNSX:VPH PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -7.63x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
North America Healthcare Industry PEG Ratio Median Figure of 47 Publicly-Listed Healthcare Companies 1.59x
Canada Market PEG Ratio Median Figure of 248 Publicly-Listed Companies 1.15x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Valeo Pharma, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Valeo Pharma's assets?
Raw Data
CNSX:VPH PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-01-31) in CAD CA$-0.05
CNSX:VPH Share Price * CNSX (2019-06-13) in CAD CA$0.55
Canada Healthcare Industry PB Ratio Median Figure of 23 Publicly-Listed Healthcare Companies 2.45x
Canada Market PB Ratio Median Figure of 2,417 Publicly-Listed Companies 1.41x
CNSX:VPH PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= CNSX:VPH Share Price ÷ Book Value per Share (both in CAD)

= 0.55 ÷ -0.05

-10.34x

* Primary Listing of Valeo Pharma.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Valeo Pharma has negative assets, we can't compare the value of its assets to the CA Healthcare industry average.

Next steps:

  1. Take a look at our analysis of VPH’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Valeo Pharma's regulatory filings and announcements.
  3. Show me more potentially undervalued companies in the Healthcare industry
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Value checks
We assess Valeo Pharma's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Healthcare industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Healthcare industry average (and greater than 0)? (1 check)
  5. Valeo Pharma has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Valeo Pharma expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Valeo Pharma has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
53.5%
Expected Healthcare industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Valeo Pharma expected to grow at an attractive rate?
  • Unable to compare Valeo Pharma's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Valeo Pharma's earnings growth to the Canada market average as no estimate data is available.
  • Unable to compare Valeo Pharma's revenue growth to the Canada market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
CNSX:VPH Future Growth Rates Data Sources
Data Point Source Value (per year)
Canada Healthcare Industry Earnings Growth Rate Market Cap Weighted Average 53.5%
Canada Healthcare Industry Revenue Growth Rate Market Cap Weighted Average 16.5%
Canada Market Earnings Growth Rate Market Cap Weighted Average 14.6%
Canada Market Revenue Growth Rate Market Cap Weighted Average 6%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
CNSX:VPH Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in CAD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
CNSX:VPH Past Financials Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income *
2019-01-31 6 -1 -3
2018-10-31 4 -1 -2
2018-07-31 3 -1 -3
2017-10-31 1 -1 -4
2016-10-31 1 -2 -1

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Valeo Pharma is high growth as no earnings estimate data is available.
  • Unable to determine if Valeo Pharma is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
CNSX:VPH Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Valeo Pharma Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:VPH Past Financials Data
Date (Data in CAD Millions) EPS *
2019-01-31 -0.07
2018-10-31 -0.07
2018-07-31 -0.06
2017-10-31 -0.12
2016-10-31 -0.06

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Valeo Pharma will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Take a look at our analysis of VPH’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. Valeo Pharma's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Healthcare companies here
  3. Valeo Pharma's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Valeo Pharma's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Canada market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Canada market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Valeo Pharma has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Valeo Pharma performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Valeo Pharma's growth in the last year to its industry (Healthcare).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Valeo Pharma does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Valeo Pharma's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Valeo Pharma's 1-year growth to the CA Healthcare industry average as it is not currently profitable.
Earnings and Revenue History
Valeo Pharma's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Valeo Pharma Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:VPH Past Revenue, Cash Flow and Net Income Data
Date (Data in CAD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-01-31 5.93 -2.81 3.79 0.01
2018-10-31 4.38 -2.44 3.22
2018-07-31 2.90 -2.73 2.68 0.13
2017-10-31 1.28 -3.62 2.98 0.13
2016-10-31 0.99 -1.28 2.84

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Valeo Pharma has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
  • It is difficult to establish if Valeo Pharma has efficiently used its assets last year compared to the CA Healthcare industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Valeo Pharma improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to its liabilities exceeding its assets.
X
Past performance checks
We assess Valeo Pharma's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Healthcare industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Valeo Pharma has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Valeo Pharma's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Valeo Pharma's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Valeo Pharma's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • Valeo Pharma's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Valeo Pharma's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Valeo Pharma has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Valeo Pharma Company Filings, last reported 4 months ago.

CNSX:VPH Past Debt and Equity Data
Date (Data in CAD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-01-31 -2.39 2.82
2018-10-31 -1.37 2.41 0.01
2018-07-31 -0.50 2.01 0.02
2017-10-31 -2.60 4.44 0.00
2016-10-31 0.96 2.36 0.21
  • Valeo Pharma has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
  • Irrelevant to check if Valeo Pharma's debt level has increased considering it has negative shareholder equity.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Valeo Pharma has less than a year of cash runway based on current free cash flow.
  • Valeo Pharma has less than a year of cash runway if free cash flow continues to reduce at historical rates of -26.4% each year.
X
Financial health checks
We assess Valeo Pharma's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Valeo Pharma has a total score of 1/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Valeo Pharma's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Valeo Pharma dividends.
If you bought CA$2,000 of Valeo Pharma shares you are expected to receive CA$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Valeo Pharma's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Valeo Pharma's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
CNSX:VPH Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
North America Healthcare Industry Average Dividend Yield Market Cap Weighted Average of 25 Stocks 1.6%
Canada Market Average Dividend Yield Market Cap Weighted Average of 335 Stocks 3.5%
Canada Minimum Threshold Dividend Yield 10th Percentile 1.2%
Canada Bottom 25% Dividend Yield 25th Percentile 2.1%
Canada Top 25% Dividend Yield 75th Percentile 5.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Valeo Pharma has not reported any payouts.
  • Unable to verify if Valeo Pharma's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Valeo Pharma's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Valeo Pharma has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Valeo Pharma's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.2%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Valeo Pharma afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Valeo Pharma has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Valeo Pharma's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Steve Saviuk
COMPENSATION CA$246,666
AGE 59
TENURE AS CEO 16.4 years
CEO Bio

Mr. Steven Saviuk, also known as Steve, CA, serves as the Chairman and Chief Executive Officer of Manitex Capital Inc. and has been its President since 1995. Mr. Saviuk serves as Chief Executive Officer and Chairman of the Board of Intasys. Mr. Saviuk co-founded Valeo Pharma Inc. in 2003 and has been its Chief Executive Officer and President since 2003 and also serves as its Director. He has been Chief Financial Officer of Cabia Goldhills, Inc. since 26, 2011. He serves as the Chairman of Chevalier Resources Inc. He served as the Chairman of Gee-Ten Ventures Inc. He served as the Chairman of Cabia Goldhills Inc. and has been its Director since October 26, 2011. He served as an Executive Chairman of Ortho Regenerative Technologies Inc. since February 5, 2015 until October 18, 2016 and served as its Interim President until November 26, 2015. Mr. Saviuk has been a Director of TECE, Inc. since October 2000 and Manitex Capital, Inc. since March 1995. He has been a Director at Earth Alive Clean Technologies Inc. since April 25, 2018. He has been Non-Independent Director of Ortho Regenerative Technologies Inc. since February 5, 2015. He serves as a Director of Lumenon Innovative Lightwave Technology, Inc. Mr. Saviuk served as a Director of Pinetree Capital Corp., since 2000 and Pinetree Capital Ltd. since March 2000. He served as a Director of Gee-Ten Ventures Inc., since 2010. He served as a Director of NSI Global Inc. Mr. Saviuk is a Chartered Accountant. Mr. Saviuk graduated from Concordia University (B.Comm). He serves as Chairman of the Board of Directors of Ortho Regenerative Technologies Inc. since March 06, 2019.

CEO Compensation
  • Steve's compensation has increased whilst company is loss making.
  • Steve's remuneration is higher than average for companies of similar size in Canada.
Management Team

Steve Saviuk

TITLE
President
COMPENSATION
CA$247K
AGE
59
TENURE
16.4 yrs

Luc Mainville

TITLE
Senior VP & CFO
COMPENSATION
CA$180K
AGE
54

Helen Saviuk

TITLE
Vice President of Operations
COMPENSATION
CA$159K

Marc Leger

TITLE
Senior VP & Chief Commercial Officer
COMPENSATION
CA$180K

Guy-Paul Allard

TITLE
VP of Legal Affairs & Corporate Secretary
Board of Directors Tenure

Average tenure and age of the Valeo Pharma board of directors in years:

0.8
Average Tenure
59
Average Age
  • The average tenure for the Valeo Pharma board of directors is less than 3 years, this suggests a new board.
Board of Directors

Richard MacKay

TITLE
Chairman
AGE
82

Steve Saviuk

TITLE
President
COMPENSATION
CA$247K
AGE
59
TENURE
16.3 yrs

Vincent Hogue

TITLE
Director
AGE
55
TENURE
0.9 yrs

Michael Wells

TITLE
Director
AGE
49
TENURE
0.6 yrs

Maureen Brennan

TITLE
Director
AGE
62
TENURE
0.6 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (CA$) Value (CA$)
05. Mar 19 Buy Luc Mainville Individual 01. Mar 19 01. Mar 19 1,000 CA$0.70 CA$700
22. Feb 19 Buy Luc Mainville Individual 20. Feb 19 22. Feb 19 4,000 CA$0.72 CA$2,786
X
Management checks
We assess Valeo Pharma's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Valeo Pharma has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Valeo Pharma Inc. acquires and markets specialty products, and markets and distributes third-party pharmaceutical products. Its product portfolio includes Synacthen, a neurology therapeutic for the treatment of severe multiple sclerosis and gout; M-Eslon, an extended release morphine sulphate used for pain management; and M-Ediat, an immediate release morphine sulphate used for pain management. The company also offers Utrogestan, a micronized progesterone indicated for luteal phase support during in vitro fertilization cycles; and Onstryv, a safinamide tablet used to treat idiopathic Parkinson’s disease. In addition, it develops Ethacrynate Sodium, a loop diuretic used to treat high blood pressure, as well as the swelling caused by diseases, such as congestive heart failure, liver failure, and kidney failure. The company was founded in 2003 and is headquartered in Kirkland, Canada.

Details
Name: Valeo Pharma Inc.
VPH
Exchange: CNSX
Founded: 2003
CA$26,140,404
47,528,008
Website: http://www.valeopharma.com
Address: Valeo Pharma Inc.
16667 Hymus Boulevard,
Kirkland,
Quebec, H9H 4R9,
Canada
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
CNSX VPH Class A Shares Canadian National Stock Exchange CA CAD 20. Feb 2019
Number of employees
Current staff
Staff numbers
18
Valeo Pharma employees.
Industry
Health Care Distributors
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/06/20 01:00
End of day share price update: 2019/06/13 00:00
Last earnings filing: 2019/04/30
Last earnings reported: 2019/01/31
Last annual earnings reported: 2018/10/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.